BridgeBio Oncology Therapeutics (BBOT) Retained Earnings (2023 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Retained Earnings of -$981000.0 for Q1 2026, up 99.72% sequentially from -$356.6 million in Q4 2025, and up 84.05% YoY from -$532996.9 in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Retained Earnings (2023 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Retained Earnings for 4 years, with the latest figure at -$981000.0 in Q1 2026.
- Quarterly Retained Earnings rose 84.05% year-over-year to -$981000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$981000.0 (up 84.05% YoY) and the FY2025 annual result came in at -$356.6 million, down 918.98% from the prior year.
- Retained Earnings advanced to -$981000.0 in Q1 2026 per BBOT's latest filing, from -$356.6 million in the prior quarter.
- Over five years, Retained Earnings peaked at $43.5 million in Q4 2024 and troughed at -$356.6 million in Q4 2025.
- A 4-year average of -$33.7 million and a median of -$3.3 million in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings jumped 177316.46% in 2024, then slumped 918.98% in 2025.
- Over 4 years, Retained Earnings stood at $24540.0 in 2023, then surged by 177316.46% to $43.5 million in 2024, then plunged by 918.98% to -$356.6 million in 2025, then soared by 99.72% to -$981000.0 in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$981000.0, -$356.6 million, and $36000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 779.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 779.19 Mn |
| Mar 31, 2026 | -981,000.00 |
| Dec 31, 2025 | -356.57 Mn |
| Sep 30, 2025 | 36,000.00 |
| Jun 30, 2025 | -7.27 Mn |
| Mar 31, 2025 | -6.15 Mn |
| Dec 31, 2024 | 43.54 Mn |
| Sep 30, 2024 | -3.52 Mn |
| Jun 30, 2024 | -3.37 Mn |
| Mar 31, 2024 | -3.22 Mn |
| Dec 31, 2023 | 24,540.00 |